Investor Presentation

Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 August 10, 2026 To To Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 051 BSE CODE: 543329 NSE SYMBOL: WINDLAS Dear Sir/ Madam, Sub: Regulation 30(6) of SEBI (LODR) Regulations, 2015 Please find enclosed herewith the Investor Presentation – Q1 FY27, for your record. Kindly take the same on record. Thanking you, Yours faithfully, For Windlas Biotech Limited Ananta Narayan Panda Company Secretary & Compliance Officer Encl: as above www.windlas.com Windlas Biotech Limited Investor Presentation – Q1FY27 Disclaimer This presentation and the accompanying slides (the “Presentation”), has been prepared by Windlas Biotech Limited (the “Company”), solely for information purposes and do not constituteanyoffer,recommendation or invitationtopurchaseor subscribeforany securities,andshallnot formthebasisorberelied onin connection with any contractorbinding commitmentwhatsoever.NoofferingofsecuritiesoftheCompanywillbemadeexceptbymeansofastatutoryofferingdocumentcontainingdetailedinformationabouttheCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, expressorimplied,whatsoever,andnorelianceshallbeplacedon,thetruth,accuracy,completeness,fairnessandreasonablenessofthecontentsofthisPresentation.ThisPresentation maynotbeallinclusiveandmaynotcontainalloftheinformationthatyoumayconsidermaterial.Anyliabilityinrespectofthecontentsof,oranyomissionfrom,thisPresentationis expresslyexcluded. CertainmattersdiscussedinthisPresentationmaycontainstatementsregardingtheCompany’smarketopportunityandbusinessprospectsthatareindividuallyandcollectivelyforward- lookingstatements. Such forward-lookingstatementsarenot guaranteesof futureperformanceand aresubjectto knownand unknown risks,uncertaintiesandassumptionsthat are difficult to predict. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation.TheCompanyassumesnoobligationtoupdateanyforward-lookinginformationcontainedinthisPresentation.Anyforward-lookingstatementsandprojectionsmadeby thirdpartiesincludedinthisPresentationarenotadoptedbytheCompanyandtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections.TheCompanyand/orits affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitationforanyclaim,proceedings,action,suits,losses,expenses,damagesorcosts)whichmaybebroughtagainstorsufferedbyanypersonasaresultofactinginrelianceuponthe whole or anypart of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwiseariseisherebyexpresslydisclaimed. Table of Contents Windlas – At a Glance Q1FY27 Highlights SCALABILITY, DURABILITY & Business Verticals PROFITABILITY Company Overview Annual Financials Windlas – Trusted Partner in Delivering Value Across the Healthcare Ecosystem Building Scale and Excellence in ~25 Years of Expertise Robust Financial Position Generic Formulations Creating Strong Entry Barriers (as of FY26) • Presence across all stages of Generics Value Chain • 5 State-of-the-Art, WHO-GMP compliant manufacturing • CAGR FY22 to FY26 with focus on Formulations -Development, plants with8,522 Mnof capacity for Tablets & Capsules, 54 • 18% Revenue Manufacturing and Marketing Mnfor Pouch & Sachets & 61 Mn for Liquid Bottles • 19%EBITDA • 8 of the Top 10 and15 of the Top 20 Indian • DSIR approved R&D laboratory & pilot scaled equipment • 15% PAT Pharma Companies serviced • 29% ROE*and32% ROCE* • IP Rights (Formulation Technology) across 99% of • 926 Customers served products sold • 4.7xAsset Turnover# • 5,644 Brandscatered to across therapeutic areas • Higher revenue share of Chronic & Sub-Chronic (53%) and • Rs 251 Cr of Strong Net Liquidity and Net Debt free Complex Generic (74%) in overall product portfolio • Fast growing in Trade Generics and Exports • Rs 104 Cr of Cashflow from Operations • 4,393 brands in Complex Generics • 546 Brandsunder Domestic Trade Generics • A+ Stable ICRA Rating • Strong Dossier development and regulatory expertise • 67 Products exported across 10 Countries • Proficient Leadership Team • Long standing Customer Relationships *For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end ofperiod. # excluding CWIP of Plant-6. Q1FY27 Highlights Management Commentary The Indian Pharmaceutical Market (IPM) witnessed a volume growth of 3.4% in Q1 FY27, reflecting a steady yet measured industry environment.Againstthisbackdrop,WindlasBiotechcontinueditsgrowthtrajectory,deliveringitshighest-everquarterlyrevenueof₹248crore, representing 18% YoY growth. This performance underscores the strength and resilience of our diversified business model, our operational excellence,andthetrustourcustomersplaceinus. We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable usto support future growth opportunities. Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectivenessofourstrategicinvestments. We remain focused on creating sustainable value through disciplined execution, talent development, client diversification, capability Mr. Hitesh Windlass enhancement, and expansion across dosage forms. I would like to thank our customers, partners and employees, shareholders for their Managing Director continuedtrustandsupport. We have started FY27 with a positive note by extending our record revenue streak to 14 consecutive quarters with 18% YoY growth to Rs 248 crore. Consistentwithourfocusonlong-termshareholdersvaluecreation,inQ1FY27thecompanyalsocompleted₹47crorebuybackinwhichpromotersdidnot participateanddeclarationofFY26dividend₹13crore(₹6.30perequityshare). ExcludingtheimpactofESOPexpenses(₹7.2Crore)whichareNon-cashinnature,ourEBITDAgrew26%YoYto₹34crore,PBTandPATgrew27%and37% YoY to ₹30 crore and ₹25 crore respectively, reflecting our continued focus on improving operational leverage. If we take into account Non-cash ESOP expenditure(₹7.2crore),thecompanyreported EBITDA₹27crore,PBT₹23croreandPAT₹18crore.ForQ1FY27EarningsPerShare(EPS)hasimprovedto ₹8.46. OurGenericFormulationsCDMOverticaldelivered29%YoYrevenuegrowthto₹207crore,drivenbycustomerexpansion,deepercustomerengagement, and new product launches. The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products.Asweexpandtheportfoliowithnewlaunchesandreplacements,weexpecttoprogressivelybridgethegap.OurExportsverticalrecorded79% YoY growth to ₹11 crore. We remain focused on long-term company level performance rather than quarterly and vertical wise fluctuations and are Ms. Komal Gupta confidentintheunderlyinggrowthopportunityinallthreeverticals. CEO & CFO Looking ahead, our priorities remain focused on strengthening strategic partnerships, expanding our offerings, achieving operational excellence, acceleratingportfoliodevelopment,anddrivingdisciplinedex [Showing first 8,000 characters — download PDF for full document]